Chorea

Current Opinion in Neurology

Volumn 9, Issue 4, 1996, Pages 298-302

  Shannon, Kathleen M ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASAL GANGLION; COGNITIVE DEFECT; GENE MUTATION; HUMAN; HUNTINGTON CHOREA; MOTOR DYSFUNCTION; PATHOGENESIS; REVIEW;

EID: 0029790548     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-199608000-00010     Document Type: Review

References (65)

1. The Huntington's Disease Cooperative Research Group: A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993, 72:971-983.
2. Albin RL: Selective neurodegeneration in Huntington's disease. [Editorial; comment]. Ann Neurol 1995, 38:835-836.
3. Sapp E, Ge P, Aizawa H, Bird E, Penney J, Young AB, Vonsattel J-P: Evidence for a preferential loss of enkephalin immunoreactivity in the external globus pallidus in low grade Huntington's disease using high resolution image analysis. Neuroscience 1995, 64:397-404.
4. Richfield EK, Maguire-Zeiss KA, Cox C, Gilmore J, Voorn P: Reduced expression of preproenkephalin in striatal neurons from Huntington's disease patients. Ann Neurol 1995, 37:335-343.
5. Turjanski N, Weeks R, Dolan R, Harding AE, Brooks DJ: Striatal D1 and D2 receptor binding in patients with Huntington's disease and other choreas. A PET study. Brain 1995, 118:689-696.
6. Schilling G, Sharp AH, Loev SJ, Wagster MV, Li SH, Stine OC, Ross, CA: Expression of the Huntington's disease (IT15) protein product in Huntington's disease patients. Hum Mol Genet 1995, 4:1365-1371.
7. Sharp AH, Loev SJ, Schilling G, Li S-H, Li X-J, Bao J, Wagster MV, Kotzuk JA, Steiner JP, Lo A et al.: Widespread expression of Huntington's disease gene (IT15) protein product. Neuron 1995, 14:1056-1074. The authors used antibodies against N-terminus and an internal epitope to localize the normal and abnormal protein products of the IT15 gene in Huntington's disease. It is a cytosolic protein associated with microtubules and membranes in cell bodies, dendrites and axons.
8. DiFiglia M, Sapp E, Chase K, Schwarz C, Melont A, Young C, Martin E, Vonsattel J-P, Carraway R, Reeves SA et al.: Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons. Neuron 1995, 14:1075-1081.
9. Gutekunst C-A, Levey AI, Heilman CJ, Whaley WL, Yi H, Nash NR, Rees HD, Madden HH, Hersch SM: Identification and localization of huntingtin in brain and human lymphoblastoid cell lines with anti-fusion protein antibodies. Proc Natl Acad Sci U S A 1995, 92:8710-8714.
10. Duyao MP, Auerbach AB, Ryan A, Persichetti F, Barnes GT, McNeil SM, Ge P, Vonsattel J-P, Gusella JF, Joyner AL, MacDonald ME: Inactivation of the mouse Huntington's disease gene homolog Hdh. Science 1995, 269:407-410.
11. Nasir J, Floresco SB, Diewert VM, Richman JM, Zeisler J, Borowski A, Marth JD, Phillips AG, Hayden MR: Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell 1995, 81:811-823. The authors selectively inactivated one or both copies of the Huntington's disease gene homologue in the mouse. Homozygous inactivation was incompatible with life. Heterozygotes had abnormal motor and cognitive behavior associated with loss of cells in the subthalamic nucleus.
12. Ide K, Nukina N, Masuda N, Goto J, Kanazawa I: Abnormal gene product identified in Huntington's disease lymphocytes and brain. Biomed Biophys Res Commun 1995, 209:1119-1125.
13. Trottier Y, Lutz Y, Stevanin G, Imbert G, Devys D, Cancel G, Saudou F, Weber C, David G, Tora L: Cellular localization of the Huntington's disease protein and discrimination of the normal and mutated form. Nature Genet 1995, 10:104-110. Monoclonal antibodies against four regions of the protein were used to study the localization of the Huntington's disease protein. In Huntington's disease, both the normal and abnormal protein products can be demonstrated. Their distribution mirrors expression of the gene.
14. Jou YS, Myers RM: Evidence from antibody studies that the CAG repeat in the Huntington disease gene is expressed in the protein. Hum Mol Genet 1995, 4:465-469.
15. Landwehrmeyer GB, McNeil SM, Dure LS, Ge P, Aizawa H, Huang Q, Ambrose CM, Duyao MP, Bird ED, Bonilla E et al.: Huntington's disease gene: regional and cellular expression in brain of normal and affected individuals. Ann Neurol 1995, 37:218-230. Using quantitative in-situ hybridization, the authors demonstrated expression of the IT15 gene in all examined brain regions without respect to their relative involvement in the Huntington's disease degenerative process.
16. 28K immunoreactivity in rat striatal neurons in vivo mimic the pattern seen in Huntington's disease. Neuroscience 1995, 65:397-407.
17. A receptor changes in the substantia nigra of the rat following quinolinic acid lesions in the striatum closely resemble Huntington's disease. Neuroscience 1995, 66:507-521.
18. Reilmann R, Rolf LH, Lange HW: Huntington's disease: the neurotoxin aspartate is increased in platelets and decreased in plasma. J Neurol Sci 1994, 127:48-53.
19. Bowling AC, Beal MF: Bioenergetic and oxidative stress in neurodegenerative diseases. Life Sci 1995, 56:1151-1571.
20. Brouillet E, Hantraye P, Ferrante RJ, Dolan R, Leroy-Willig A, Kowall NW, Beal MF: Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. Proc Natl Acad Sci U S A 1995, 92:7105-7109. Parenteral administration of 3-NP, an inhibitor of mitochondrial function, reproduces a behavioral and pathological syndrome similar to Huntington's disease.
21. Borlongan CV, Koutouzis TK, Randall TS, Freeman TB, Cahill DW, Sanberg PR: Systemic 3-nitropropionic acid: behavioral deficits and striatal damage in adult rats. Brain Res Bull 1995, 36:549-556.
22. + ATPase. Eur J Neurosci 1995, 7:1674-1683.
23. Horton TM, Graham BH, Corral-Debrinski M, Shoffner JM, Kaufman AE, Beal MF, Wallace D: Marked increase in mitochondrial DNA deletion levels in the cerebral cortex of Huntington's disease patients. Neurology 1995, 45:1879-1883.
24. Portera-Cailliau C, Hedreen JC, Price DL, Koliatsos VE: Evidence for apoptotic cell death in Huntington disease and excitotoxic animal models. J Neurosci 1995, 15:3775-3787.
25. Thomas LB, Gates DJ, Richfield EK, O'Brien TF, Schweitzer JB, Steindler DA: DNA end labeling (TUNEL) in Huntington's disease and other neuropathological conditions. Exp Neurol 1995, 133:265-272. Apoptotic or programmed cell death is characterized by endonuclease-mediated internucleosomal DNA fragmentation which can be studied using terminal transferase-mediated deoxyuridine triphosphate biotin nick end labelling. These methods demonstrate apoptosis in both Huntington's disease and excitotoxic lesions, but demonstrate important differences between Huntington's disease and the excitotoxic model of Huntington's disease.
26. Claes S, Van Zand K, Legius E, Dom R, Malfroid M, Baro F, Godderis J, Cassiman J-J: Correlations between triplet repeat expansion and clinical features in Huntington's disease. Arch Neurol 1995, 52:749-753.
27. n repeats in parent-offspring pairs with Huntington disease. Am J Hum Genet 1995, 57:593-602. The authors studied 277 parent-child pairs with Huntington's disease. The phenomenon of anticipation was confirmed. In paternal transmission, the increase in CAG repeat number correlated with the size of the mutation. This relationship was not true in maternal transmission.
28. n repeat, in Huntington's disease. Hum Genet 1995, 95:231-232.
29. Norremolle A, Sorensen SA, Fenger K, Hasholt L: Correlation between magnitude of CAG repeat length alterations and length of the paternal repeat in paternally inherited Huntington's disease. Clin Genet 1995, 47:113-117.
30. Thompson PD, Berardelli A, Rothwell JC, Day BL, Dick JPR, Benecke R, Marsden CD: The coexistence of bradykinesia and chorea in Huntington's disease and its implications for theories of basal ganglia control of movement. Brain 1988, 111:223-244.
31. Garcia Ruiz PJ, Mena MA, Sanchez Bernardos V, Diaz Neira W, Gimenez Roldan S, Benitez J, Garcia de Yebenes J: Cerebrospinal fluid homovanillic acid is reduced in untreated Huntington's disease. Clin Neuropharm 1995, 18:58-63.
32. Georgiou N, Bradshaw JL, Phillips JG, Chiu E, Bradshaw JA: Reliance on advance information and movement sequencing in Huntington's disease. Mov Disord 1995, 10:472-481.
33. Swerdlow NR, Paulsen J, Braff DL, Butters N, Geyer MA, Swenson MR: Impaired prepulse inhibition of acoustic and tactile startle response in patients with Huntington's disease. J Neurol Neurosurg Psychiatr 1995, 58:192-200.
34. Sprengelmeyer R, Canavan AGM, Lange HW, Homberg V: Associative learning in degenerative neostriatal disorders: contrasts in explicit and implicit remembering between Parkinson's and Huntington's diseases. Mov Disord 1995, 10:51-65.
35. Lange KW, Sahakian BJ, Quinn NP, Marsden CD, Robbins TW: Comparison of executive and visuospatial memory function in Huntington's disease and dementia of Alzheimer type matched for degree of dementia. J Neurol Nerosurg Psychiatr 1995, 58:598-606.
36. Mattis S: Mental status examination for organic mental syndrome in the elderly patient. In Geriatric psychiatry. Edited by Bellack L, Karusu TB. New York: Grune and Stratton; 1976:77-121.
37. Paulsen JS, Butters N, Sadek JR, Johnson SA, Salmon DP, Swerdlow NR, Swenson MR: Distinct cognitive profiles of cortical and subcortical dementia in advanced illness. Neurology 1995, 45:951-956.
38. Lundervold AJ, Reinvang I: Variability in cognitive function among persons at high genetic risk of Huntington's disease. Acta Neurol Scand 1995, 91:462-469.
39. Foroud T, Siemers E, Kleindorfer D, Bill DJ, Hodes ME, Norton JA, Conneally PM, Christian JC: Cognitive scores in carriers of Huntington's disease gene compared to noncarriers. Ann Neurol 1995, 37:657-664.
40. Rosenberg NK, Sorensen SA, Christensen AL: Neuropsychological characteristics of Huntington's disease carriers: a double blind study. J Med Genet 1995, 32:600-604.
41. Blackmore L, Simpson SA, Crawford JR: Cognitive performance in UK sample of presymptomatic people carrying the gene for Huntington's disease. J Med Genet 1995, 32:358-362.
42. Giordani B, Berent S, Boivin MJ, Penney JB, Lehtinen S, Markel DS, Hollingsworth Z, Butterbaugh G, Hichwa RD, Gusella JF, Young AB: Longitudinal neuropsychological and genetic linkage analysis of persons at risk for Huntington's disease. Arch Neurol 1995, 52:59-64. Four groups of patients (eight each gene-positive at-risk, gene-negative at-risk, normal control and Huntington's disease) had serial neuropsychological testing over 4 years. At-risk subjects performed more poorly than controls, suggesting social or environmental effects in Huntington's disease families, but no specific abnormalities were associated with the asymptomatic gene-carrier state.
43. Feigen A, Kieburtz K, Bordwell K, Como P, Steinberg K, Sotack J, Zimmerman C, Hickey C, Orme C, Shoulson I: Functional decline in Huntington's disease. Mov Disord 1995, 10:211-214. A total of 129 Huntington's disease patients were examined serially in order to determine the rate of decline in untreated disease. Total functional capacity declined by 0.63 ± 0.75 units per year. This information will be useful in designing clinical trials of putative protective therapies.
44. Peyser CE, Folstein M, Chase GA, Starkstein S, Brandt J, Cockrell JR, Bylsma F, Coyle JT, McHugh PR, Folstein SE: Trial of d-alpha-tocopherol in Huntington's disease. Am J Psychiatry 1995, 152:1771-1775.
45. Reading PJ, Dunnett SB: Embryonic striatal grafts reverse the disinhibitory effects of ibotenic acid lesions of the ventral striatum. Exp Brain Res 1995, 105:76-86.
46. Campbell K, Wictorin K, Bjorklund A: Neurotransmitter-related gene expression in intrastriatal striatal transplants. I. Phenotypical characterization of striatal and non-striatal graft regions. Neuroscience 1995, 64:17-33.
47. Campbell K, Wictorin K, Bjorklund A: Neurotransmitter-related gene expression in intrastriatal striatal transplants. II. Characterization of efferent projecting graft neurons. Neuroscience 1995, 64:35-47.
48. Peschanski M, Cesaro P, Hantraye P: Rationale for intrastriatal grafting of striatal neuroblasts in patients with Huntington's disease. Neuroscience 1995, 68:273-285. The authors review the evidence that suggests intrastriatal grafting of striatal neuroblasts may be useful in Huntington's disease.
49. Madrazo I, Franco-Bourland RE, Castrejon H, Cuevas C, Ostrosky-Solis F: Fetal striatal homotransplantation for Huntington's disease: first two case reports. Neurol Res 1995, 17:312-315.
50. MacMillan JC, Davies P, Harper PS: Molecular diagnostic analysis for Huntington's disease: a prospective evaluation. J Neurol Neurosurg Psychiatry 1995, 58:496-498.
51. Jankovic J, Beach J, Ashizawa T: Emotional and functional impact of DNA testing on patients with symptoms of Huntington's disease. J Med Genet 1995, 32:516-518.
52. Quaid KA, Wesson MK: Exploration of the effects of predictive testing for Huntington disease on intimate relationships. Am J Med Gen 1995, 57:46-51.
53. Britton JW, Uitti RH, Ahlskog JE, Robinson RG, Kremer B, Hayden MR: Hereditary late-onset chorea without significant dementia: genetic evidence for substantial phenotypic variation in Huntington's disease. Neurology 1995, 45:443-447.
54. Yapijakis C, Kapaki E, Zournas C, Rentzos M, Loukopoulos D, Papageorgiou C: Exclusion mapping of the benign hereditary chorea gene from the Huntington's disease locus: report of a family. Clin Genet 1995, 47: 133-138.
55. Shinotoh H, Calne DB, Snow B, Hayward M, Kremer B Theilmann J, Hayden MR: Normal CAG repeat length In the Huntington's disease gene in senile chorea. Neurology 1994, 44:2183-2184.
56. Nelson I, Hanna MG, Alsanjari N, Scaravilli F, Morgan-Hughes JA, Harding AE: A new mitochondrial DNA mutation associated with progressive dementia and chorea: a clinical pathological and molecular genetic study. Ann Neurol 1995, 37:400-403.
57. Potter NT, Meyer MA, Zimmerman AW, Eisenstadt ML, Anderson IJ: Molecular and clinical findings in a family with dentatorubral-pallidoluysian atrophy. Ann Neurol 1995, 37:273-277. Fourteen affected members of a single family with dentatorubral-pallidoluysian atrophy are described. Clinical findings and molecular biology are reviewed.
58. Koide R, Ikeuchi, T Onodera, O: Unstable expansion of CAG repeat in hereditary dentatorubral-pallidoluysian atrophy (DRPLA). Nature Genet 1994, 6:9-13.
59. Clark JD, Pahwa R, Koller C Morales D: Diabetes mellitus presenting as paroxysmal kinesiogenic dystonic choreoathetosis. [Letter]. Mov Disord 1995, 10:353-355.
60. Furie R, Ishikawa T, Dhawan V, Eidelberg D: Alternating hemichorea in primary antiphospholipid syndrome: evidence for contralateral striatal hypermetabolism. Neurology 1994, 44:2197-2199.
61. Traill Z, Pike M, Byrne J: Sydenham's chorea: a case showing reversible striatal abnormalities on CT and MRI. Dev Med Child Neurol 1995, 37:270-273.
62. Swedo SE: Sydenham's chorea. JAMA 1994, 272:1788-1791.
63. Wang H-S, Kuo M-F, Huang S-C, Chou M-L: Choreoathetosis as an initial sign of relapsing of herpes simplex encephalitis. Pediatr Neurol 1994, 11:341-345.
64. Weeks RA, Clough CG: Hemichorea due to cryptococcal meningitis. Mov Disord 1995, 10:522.
65. Sinard JH, Hedreen JC: Neuronal loss from the subthalamic nuclei in a patient with progressive chorea. Mov Disord 1995, 10:305-311.